Design of Marker Panels for Prediction of Neoadjuvant Chemotherapy Response of Triple-Negative Breast Tumors Based on the Results of Genome-Wide DNA Methylation Screening-Reference-Cited by-同舟云学术

Design of Marker Panels for Prediction of Neoadjuvant Chemotherapy Response of Triple-Negative Breast Tumors Based on the Results of Genome-Wide DNA Methylation Screening

Published:2022-07 Issue:7 Volume:58 Page:835-843
ISSN:1022-7954
Container-title:Russian Journal of Genetics
language:en
Short-container-title:Russ J Genet

Author:

Kalinkin A. I.,Sigin V. O.,Ignatova E. O.,Frolova M. A.,Kuznetsova E. B.,Vinogradov I. Y.,Vinogradov M. I.,Vinogradov I. I.,Nemtsova M. V.,Zaletaev D. V.,Tanas A. S.,Strelnikov V. V.

Publisher

Pleiades Publishing Ltd

Subject

Genetics

Link

https://link.springer.com/content/pdf/10.1134/S1022795422070080.pdf

Reference38 articles.

1. Echeverria, G.V., Ge, Z., Seth, S., et al., Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state, Sci. Transl. Med., 2019, vol. 11, no. 488. https://doi.org/10.1126/scitranslmed.aav0936

2. Schmid, P., Cortes, J., Pusztai, L., et al., Pembrolizumab for early triple-negative breast cancer, New Engl. J. Med., 2020, vol. 382, no. 9, pp. 810—821. https://doi.org/10.1056/NEJMoa1910549

3. Pandy, J.G.P., Balolong-Garcia, J.C., Cruz-Ordinario, M.V.B., and Que, F.V.F., Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review, BMC Cancer, 2019, vol. 19, no. 1, pp. 1—9. https://doi.org/10.1186/s12885-019-6253-5

4. Penault-Llorca, F. and Viale, G., Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective, Ann. Oncol., 2012, vol. 23, pp. vi19—vi22. https://doi.org/10.1093/annonc/mds190

5. Carey, L.A., Dees, E.C., Sawyer, L., et al., The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin. Cancer Res., 2007, vol. 13, no. 8, pp. 2329—2334. https://doi.org/10.1158/1078-0432.CCR-06-1109